Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
复制标题
DOI：
10.1007/s00432-020-03329-0
复制
发表时间：
2021-01
影响因子：
3.6
通讯作者：
Ohe Y
中科院分区：
文献类型：
--
作者：
Masuda K;Horinouchi H;Tanaka M;Higashiyama R;Shinno Y;Sato J;Matsumoto Y;Okuma Y;Yoshida T;Goto Y;Yamamoto N;Ohe Y
多项研究表明，携带表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 患者对程序性死亡 1 (PD-1) 抑制剂治疗的临床结果较差。然而，目前尚不清楚具有高程序性死亡配体-1（PD-L1）表达（肿瘤比例评分 ≥ 50%）的EGFR突变非小细胞肺癌是否对PD-1抑制剂有反应。我们回顾性调查了2016年1月至2018年12月期间接受PD-1抑制剂的NSCLC，以评估PD-1抑制剂对EGFR突变和PD-L1高表达患者的疗效。有 153 名 PD-L1 表达水平较高的患者，EGFR 突变患者 (n = 17) 的中位无进展生存期 (mPFS) 为 5.3 个月 [95% 置信区间 (CI) 1.3–12.4 个月]，野生型 EGFR 患者的中位无进展生存期 (mPFS) 为 8.3 个月 (95% CI 6.0–11.7 个月) (n = 136；风险比 (HR) 1.62；95% CI 0.83–2.87）。在 PD-L1 低表达组的 110 名患者中，EGFR 突变患者 (n = 18) 的 mPFS 为 1.6 个月（95% CI 1.3–5.9 个月），野生型 EGFR 患者（n = 92；HR 2.59；HR 2.59）的 mPFS 为 3.8 个月（95% CI 2.5–5.9 个月）。 95% CI 1.48–4.31）。与野生型 EGFR 和低 PD-L1 表达组相比，EGFR 突变和高 PD-L1 表达组的 PFS HR 为 0.97 (95% CI 0.56–1.59)。 PD-1抑制剂可以作为EGFR突变和PD-L1高表达的NSCLC的治疗选择之一。
Several studies have demonstrated that non-small cell lung cancer patients (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations have poor clinical outcomes in response to treatment with programmed death-1 (PD-1) inhibitors. However, it remains unclear whether EGFR-mutated NSCLCs with a high programmed death-ligand-1 (PD-L1) expression (tumor proportion score ≥ 50%) respond to PD-1 inhibitors. We retrospectively investigated the NSCLCs who had received PD-1 inhibitors between January 2016 and December 2018 to assess the efficacy of PD-1 inhibitors in patients with an EGFR mutation and high PD-L1 expression. There were 153 patients with a high PD-L1 expression level, and the median progression-free survival (mPFS) was 5.3 months [95% confidence interval (CI) 1.3–12.4 months] in the patients with EGFR mutations (n = 17) and 8.3 months (95% CI 6.0–11.7 months) in those with wild-type EGFR (n = 136; hazard ratio (HR) 1.62; 95% CI 0.83–2.87). Among the 110 patients in the low PD-L1 expression group, the mPFS was 1.6 months (95% CI 1.3–5.9 months) in the patients with EGFR mutations (n = 18) and 3.8 months (95% CI 2.5–5.9 months) in those with wild-type EGFR (n = 92; HR 2.59; 95% CI 1.48–4.31). The HR for PFS in the group with EGFR mutations and high PD-L1 expression was 0.97 (95% CI 0.56–1.59) compared to the group with wild-type EGFR and low PD-L1 expression. PD-1 inhibitors can serve as one of the treatment options for NSCLCs with an EGFR mutation and high PD-L1 expression.
登录
查看更多内容
DOI：
10.1016/j.jtho.2018.03.035
发表时间：
2018-08
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者：
Garon EB
DOI：
10.1158/1078-0432.ccr-15-3101
发表时间：
2016-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Gainor JF;Shaw AT;Sequist LV;Fu X;Azzoli CG;Piotrowska Z;Huynh TG;Zhao L;Fulton L;Schultz KR;Howe E;Farago AF;Sullivan RJ;Stone JR;Digumarthy S;Moran T;Hata AN;Yagi Y;Yeap BY;Engelman JA;Mino-Kenudson M
通讯作者：
Mino-Kenudson M
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS
DOI：
10.1016/s0140-6736(16)32517-x
发表时间：
2017-01-21
期刊：
Lancet (London, England)
影响因子：
--
作者：
Rittmeyer A;Barlesi F;Waterkamp D;Park K;Ciardiello F;von Pawel J;Gadgeel SM;Hida T;Kowalski DM;Dols MC;Cortinovis DL;Leach J;Polikoff J;Barrios C;Kabbinavar F;Frontera OA;De Marinis F;Turna H;Lee JS;Ballinger M;Kowanetz M;He P;Chen DS;Sandler A;Gandara DR;OAK Study Group
通讯作者：
OAK Study Group
影响因子：
50.5
作者：
Schoenfeld, A. J.;Arbour, K. C.;Hellmann, M. D.
通讯作者：
Hellmann, M. D.